Open Innovators Join free
News / 26 Oct 2026
PharmExec · 26 Oct 2026 · Collaborations & pilots

Bristol Myers Squibb gets neuroscience rights to Pathos AI's Foundry platform

Pathos AI, Bristol Myers Squibb and Tempus AI agreed multi-year collaborations on data and agentic AI for Alzheimer's and other neurological diseases. BMS gets access to the Pathos Foundry platform across its R&D and three-year exclusive rights in neuroscience; Pathos licenses a Tempus dataset for $55 million over five years. BMS also led the Pathos $237 million Series E.

Why it matters: Combining a commercial deal with a lead investment ties a pharma company closely to a startup's platform roadmap.
Bristol Myers SquibbAI & machine learningBiotechData & analytics
Read the original at PharmExec

Related collaborations

Partnership
Bristol Myers Squibb × Pathos AIPathos AI: Foundry platform access and neuroscience rights for BMS
Partnership
Bristol Myers Squibb × Chai DiscoveryChai Discovery: AI models for BMS antibody discovery
Roll-out
BASS GmbH × teamazingteamazing: shop-floor AI pilot leads to three-year contract
Investment
Johnson & Johnson × Delix TherapeuticsDelix Therapeutics: J&J Innovation co-leads USD 100M Series C
All collaborations